Unexpected Residual Gastric Contents in a Patient After Holding Semaglutide After Standard Fasting Guidelines: A Case Report.
A A Pract · 2026
Last updated 2026-07-22| Journal | A A Pract, 2026 |
|---|---|
| Citations | 0 |
| Molecules | semaglutide |
Abstract
A 58-year-old man scheduled for an elective upper endoscopy followed standard preprocedural fasting guidelines and withheld one weekly dose of semaglutide, a glucagon-like peptide-1 (GLP-1) receptor agonist (GLP-1 RA). Despite these measures, substantial residual gastric contents led to procedure cancelation. Notably, the same patient previously underwent a combined upper endoscopy and colonoscopy after withholding an identical semaglutide weekly dose, with no residual gastric contents were observed. This case suggests that adherence to standard preprocedural recommendations alone may not reliably prevent residual gastric contents in patients receiving GLP-1 RAs, and that a 24-hour liquid diet may be necessary.
Verbatim abstract via PubMed 41705849 ↗
Related research
- Semaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes.
- Once-Weekly Semaglutide in Adults with Overweight or Obesity.
- Semaglutide and Cardiovascular Outcomes in Obesity without Diabetes.
- A Placebo-Controlled Trial of Subcutaneous Semaglutide in Nonalcoholic Steatohepatitis.
- Tirzepatide versus Semaglutide Once Weekly in Patients with Type 2 Diabetes.
- Oral Semaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes.
- Effects of Semaglutide on Chronic Kidney Disease in Patients with Type 2 Diabetes.
- Semaglutide in Patients with Heart Failure with Preserved Ejection Fraction and Obesity.